ABSTRACT
Aquaporins (AQPs) are a family of membrane proteins that function as channels facilitating water transport in response to osmotic gradients. These play critical roles in several normal physiological and pathological states and are targets for drug discovery. Selective inhibition of the AQP1 water channel may provide a new approach for the treatment of several disorders including ocular hypertension/glaucoma, congestive heart failure, brain swelling associated with a stroke, corneal and macular edema, pulmonary edema, and otic disorders such as hearing loss and vertigo. We developed a high-throughput assay to screen a library of compounds as potential AQP1 modulators by monitoring the fluorescence dequenching of entrapped calcein in a confluent layer of AQP1-overexpressing CHO cells that were exposed to a hypotonic shock. Promising candidates were tested in a Xenopus oocyte-swelling assay, which confirmed the identification of two lead classes of compounds belonging to aromatic sulfonamides and dihydrobenzofurans with IC50 s in the low micromolar range. These selected compounds directly inhibited water transport in AQP1-enriched stripped erythrocyte ghosts and in proteoliposomes reconstituted with purified AQP1. Validation of these lead compounds, by the three independent assays, establishes a set of attractive AQP1 blockers for developing novel, small-molecule functional modulators of human AQP1.
Subject(s)
Aquaporin 1/antagonists & inhibitors , Animals , CHO Cells , Cricetinae , Cricetulus , HumansABSTRACT
Through medicinal chemistry lead optimization studies focused on calculated properties and guided by X-ray crystallography and computational modeling, potent pan-JNK inhibitors were identified that showed submicromolar activity in a cellular assay. Using in vitro ADME profiling data, 9t was identified as possessing favorable permeability and a low potential for efflux, but it was rapidly cleared in liver microsomal incubations. In a mouse pharmacokinetics study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma clearance. Brain exposure at a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the compound was coadministered with the pan-cytochrome P450 inhibitor 1-aminobenzotriazole.
Subject(s)
Mitogen-Activated Protein Kinase 10/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Animals , Blood-Brain Barrier/drug effects , Chemistry Techniques, Synthetic , Crystallography, X-Ray , Cytochrome P-450 Enzyme Inhibitors/chemistry , Cytochrome P-450 Enzyme Inhibitors/pharmacology , Disease Models, Animal , Dogs , Drug Evaluation, Preclinical/methods , Half-Life , Humans , Huntington Disease/drug therapy , Huntington Disease/metabolism , Inhibitory Concentration 50 , Madin Darby Canine Kidney Cells/drug effects , Mice , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Mitogen-Activated Protein Kinase 10/chemistry , Molecular Structure , Protein Kinase Inhibitors/chemical synthesis , Pyrazoles/chemistry , Pyrimidines/chemistry , Structure-Activity RelationshipSubject(s)
Actinomycetales/metabolism , Anthraquinones/pharmacology , Anti-Infective Agents/pharmacology , Anthraquinones/isolation & purification , Anti-Infective Agents/isolation & purification , Cell Line , Fibroblasts/drug effects , Fibroblasts/metabolism , Hep G2 Cells , Humans , Microbial Sensitivity TestsABSTRACT
Three new antibiotics, neopyrrolomycins B (1), C (2), and D (3), with potent activity against Gram-positive pathogens were discovered. They exhibited MIC values < 1 microg/mL versus a number of resistant strains. The compounds were obtained from the ethyl acetate extracts of a Streptomyces sp. after purification by column chromatography and RP-HPLC. Their structures were elucidated using X-ray crystallography (1) and NMR spectroscopy (2 and 3).
Subject(s)
Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/pharmacology , Streptomyces/chemistry , Anti-Bacterial Agents/chemistry , Crystallography, X-Ray , Drug Resistance, Bacterial/drug effects , Drug Screening Assays, Antitumor , Enterococcus faecium/drug effects , Escherichia coli/drug effects , Humans , Klebsiella pneumoniae/drug effects , Methicillin-Resistant Staphylococcus aureus/drug effects , Microbial Sensitivity Tests , Molecular Conformation , Molecular Structure , Nuclear Magnetic Resonance, Biomolecular , Pseudomonas aeruginosa/drug effects , Pyrroles/chemistry , Pyrroles/isolation & purification , Pyrroles/pharmacology , Streptococcus pneumoniae/drug effects , Vancomycin/pharmacologyABSTRACT
Two new xanthone antibiotics, citreamicin delta (1) and epsilon (2), with potent activity against Gram-positive pathogens including multidrug-resistant Staphylococcus aureus (MDRSA) were discovered. Compounds 1 and 2 exhibited MIC values < 1 microg/mL versus a number of resistant strains. The compounds were obtained from EtOAc extracts of Streptomyces vinaceus and were purified by countercurrent chromatography and reversed-phase HPLC. Their structures were elucidated using primarily NMR and mass spectroscopy.
Subject(s)
Drug Resistance, Multiple, Bacterial/drug effects , Gram-Positive Bacteria/drug effects , Staphylococcus aureus/drug effects , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Chromatography, High Pressure Liquid , Humans , Microbial Sensitivity Tests , Molecular Structure , Oxazoles/chemistry , Oxazoles/pharmacologyABSTRACT
Resistance to currently available antibiotics has become a widely recognized crisis in the medical community. To address this, many companies and researchers are refocusing their attention towards natural products, which have an excellent track record of producing effective antibacterial drugs. The AMRI natural product library was screened for activity against multi-drug resistant Staphylococcus aureus (MDRSA). The active samples were counter screened for cytotoxicity against the human hepatocellular carcinoma HepG2 cell line to determine an in vitro therapeutic index (in vitro TI). Those samples with a high in vitro TI were selected for fractionation and dereplication. This led to the discovery of a new anthracycline structure. This metabolite, named mutactimycin E (1), exhibited moderate activity against several gram positive organisms. Here we report the isolation, structure elucidation and biological activities of this new compound.
Subject(s)
Anthracyclines/pharmacology , Anti-Bacterial Agents/pharmacology , Gram-Positive Bacteria/drug effects , Anthracyclines/chemistry , Anthracyclines/isolation & purification , Anthracyclines/toxicity , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/toxicity , Cell Line , Hepatocytes/drug effects , Humans , Molecular Structure , Small Molecule Libraries , Spectrum AnalysisABSTRACT
B cells stimulated by the combination of CD40L plus anti-Ig were screened for upregulated gene expression in an unbiased fashion through differential display. An inducible transcript was obtained that corresponds to a sequence previously isolated from pre-B cells and termed murine Sik-similar protein (mSSP). The mSSP gene is predominantly expressed in lymphoid tissues, including spleen and thymus, as well as testis, with lesser amounts in kidney and ovary. Among lymphocyte cell lines, mSSP expression varies widely. The mSSP protein is localized to the nucleus in NIH3T3 cells, and its expression in BAL-17 B cells varies with cell cycle progression. Expression of mSSP increased significantly within the first hours of B cell treatment with either CD40L, anti-IgM, or phorbol myristate acetate (PMA) with or without ionomycin. The predicted amino acid sequence of mSSP bears some homology to proteins involved in ribosomal RNA synthesis and processing. mSSP is a previously identified pre-B cell gene now shown for the first time to be an activation-responsive transcript in mature, primary B cells.
